Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 4, 2024
Data Byte
Nine PDUFA dates on FDA’s December calendar
Ionis’ first wholly owned product among three rare disease therapies up for approval. BMS expecting decision on subcutaneous Opdivo
BioCentury | Nov 15, 2024
Product Development
Pharmas challenging Novo and Lilly in obesity
An analysis of which major pharmas are in, out, or still deciding whether to take on obesity heavyweights Eli Lilly and Novo Nordisk
BioCentury | Nov 6, 2024
Product Development
Alzheimer’s roundup: Clinical progress and setbacks at CTAD
Readouts showcase promise of Roche’s brainshuttle; plus mixed results from Lilly, Lexeo and Anavex
BioCentury | Oct 22, 2024
Product Development
Otsuka to take advantage of newly charted accelerated pathway for IgA nephropathy
BioCentury’s Clinical Report analyzes a pair of GLP-1 agonist updates, plus data from Amylyx’s ALS therapy in a new indication, and more
BioCentury | Oct 9, 2024
Data Byte
Five advisory committee meetings on FDA’s October docket
Panels include discussions on NDAs for Stealth’s Barth syndrome program and Lexicon’s Zynquista, plus how to prepare for a bird flu pandemic
BioCentury | Oct 8, 2024
Emerging Company Profile
Judo Bio: Making the kidney the access point for siRNA therapies
New Cambridge, Mass., biotech is delivering oligonucleotides to the kidneys to treat systemic and renal diseases
BioCentury | Aug 15, 2024
Finance
No sleep for the biotech bear: Restructurings abound in August
At least 20 companies have trimmed pipelines, cut staff or otherwise re-jiggered strategies in past two weeks to extend runway
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | Mar 19, 2024
Product Development
Clinical report: Crinetics ready to advance oral acromegaly therapy to FDA
Plus: Phase IIb setback for Spruce, Inventiva combination in MASH, and more
BioCentury | Mar 15, 2024
Finance
Public equity report: PIPEs for Lexicon, Cybin, Regulus, Lexeo
Companies raise cash as they eye paths forward in diabetes, depression, kidney disease and Friedreich ataxia
Items per page:
1 - 10 of 500